2017 -- H 5035 | |
======== | |
LC000191 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2017 | |
____________ | |
A N A C T | |
RELATING TO FOOD AND DRUGS-UNIFORM CONTROLLED SUBSTANCES ACT | |
| |
Introduced By: Representatives McNamara, Diaz, Morin, Shanley, and McLaughlin | |
Date Introduced: January 06, 2017 | |
Referred To: House Judiciary | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Section 21-28-2.08 of the General Laws in Chapter 21-28 entitled "Uniform |
2 | Controlled Substances Act" is hereby amended to read as follows: |
3 | 21-28-2.08. Contents of schedules. |
4 | Schedule I |
5 | (a) Schedule I shall consist of the drugs and other substances, by whatever official name, |
6 | common or usual name, chemical name, or brand name designated, listed in this section. |
7 | (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
8 | following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and |
9 | ethers whenever the existence of the isomers, esters, ethers, and salts is possible within the |
10 | specific chemical designation: |
11 | (1) Acetylmethadol |
12 | (2) Allylprodine |
13 | (3) Alphacetylmethadol |
14 | (4) Alphameprodine |
15 | (5) Alphamethadol |
16 | (6) Benzethidine |
17 | (7) Betacetylmethadol |
18 | (8) Betameprodine |
19 | (9) Betamethadol |
| |
1 | (10) Betaprodine |
2 | (11) Clonitazene |
3 | (12) Dextromoramide |
4 | (13) Difenoxin |
5 | (14) Diampromide |
6 | (15) Diethylthiambutene |
7 | (16) Dimenoxadol |
8 | (17) Dimepheptanol |
9 | (18) Dimethylthiambutene |
10 | (19) Dioxaphetyl butyrate |
11 | (20) Dipipanone |
12 | (21) Ethylmethylthiambutene |
13 | (22) Etonitazene |
14 | (23) Extoxerdine |
15 | (24) Furethidine |
16 | (25) Hydroxypethidine |
17 | (26) Ketobemidone |
18 | (27) Levomoramide |
19 | (28) Levophenacylmorphan |
20 | (29) Morpheridine |
21 | (30) Noracymethadol |
22 | (31) Norlevorphanol |
23 | (32) Normethadone |
24 | (33) Norpipanone |
25 | (34) Phenadoxone |
26 | (35) Phenampromide |
27 | (36) Phenomorphan |
28 | (37) Phenoperidine |
29 | (38) Piritramide |
30 | (39) Proheptazine |
31 | (40) Properidine |
32 | (41) Propiram |
33 | (42) Racemoramide |
34 | (43) Trimeperidone |
| LC000191 - Page 2 of 17 |
1 | (44) Tilidine |
2 | (45) Alpha-methylfentanyl |
3 | (46) Beta-hydroxy-3-methylfentanyl other names: |
4 | N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl] Nphenylpropanamide |
5 | (47) 3,4-Dichloro-N-[2-(dimethylamino) cyclohexyl]-N-methylbenzamide, its isomers, |
6 | esters, ethers, salts and salts of isomers, esters and ethers (Other names: U-47700)-(9547). |
7 | (c) Opium Derivatives. Unless specifically excepted or unless listed in another schedule, |
8 | any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the |
9 | existence of the salts, isomers, and salts of isomers is possible within the specific chemical |
10 | designation: |
11 | (1) Acetorphine |
12 | (2) Acetyldihydrocodeine |
13 | (3) Benzylmorphine |
14 | (4) Codeine methylbromide |
15 | (5) Codeine-N-Oxide |
16 | (6) Cyprenorphine |
17 | (7) Desomorphine |
18 | (8) Dihydromorphine |
19 | (9) Etorphine (Except hydrochloride salt) |
20 | (10) Heroin |
21 | (11) Hydromorphinol |
22 | (12) Methyldesorphine |
23 | (13) Methylihydromorphine |
24 | (14) Morphine methylbromide |
25 | (15) Morphine methylsulfonate |
26 | (16) Morphine-N-Oxide |
27 | (17) Myrophine |
28 | (18) Nococodeine |
29 | (19) Nicomorphine |
30 | (20) Normorphine |
31 | (21) Pholcodine |
32 | (22) Thebacon |
33 | (23) Drotebanol |
34 | (d) Hallucinogenic Substances. Unless specifically excepted or unless listed in another |
| LC000191 - Page 3 of 17 |
1 | schedule, any material, compound, mixture, or preparation that contains any quantity of the |
2 | following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers |
3 | whenever the existence of the salts, isomers, and salts of isomers is possible within the specific |
4 | chemical designation (for purposes of this subsection only, the term "isomer" includes the optical, |
5 | position, and geometric isomers): |
6 | (1) 3, 4-methylenedioxy amphetamine |
7 | (2) 5-methoxy-3, 4-methylenedioxy amphetamine |
8 | (3) 3, 4, 5-trimethoxy amphetamine |
9 | (4) Bufotenine |
10 | (5) Diethyltryptamine |
11 | (6) Dimethyltryptamine |
12 | (7) 4-methyl 2, 5-dimethoxyamphetamine |
13 | (8) Ibogaine |
14 | (9) Lysergic acid diethylamide |
15 | (10) Marihuana |
16 | (11) Mescaline |
17 | (12) Peyote. Meaning all parts of the plant presently classified botanically as Lophophora |
18 | Williamsii Lemair whether growing or not; the seeds of the plant; any extract from any part of the |
19 | plant; and any compound, manufacture, salt, derivative, mixture, or preparation of the plant, its |
20 | seeds or extracts. |
21 | (13) N-ethyl-3-piperidyl benzilate |
22 | (14) N-methyl-3-piperidyl benzilate |
23 | (15) Psilocybin |
24 | (16) Psilocyn |
25 | (17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the |
26 | plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and |
27 | their isomers with similar chemical structure and pharmacological activity such as the following: |
28 | delta 1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans |
29 | tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and |
30 | their optical isomer. (Since nomenclature of these substances is not internationally standardized, |
31 | compounds of these structures, regardless of numerical designation of atomic positions covered). |
32 | (18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2- |
33 | Thienyl analog of phencyclidine: TPCP |
34 | (19) 2,5 dimethoxyamphetamine |
| LC000191 - Page 4 of 17 |
1 | (20) 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha- |
2 | methylphenethyamine: 4-bromo-2,5-DMA |
3 | (21) 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine: |
4 | paramethoxyamphetamine: PMA |
5 | (22) Ethylamine analog of phencyclidine. N-ethyl-1- phenylcyclohexylamine, (1- |
6 | phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE |
7 | (23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)- pyrrolidine PCPy, PHP |
8 | (24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- |
9 | trimethyl-6H-dibenz o (b,d) pyran: Synhexyl. |
10 | (25) Salvia Divinorum (Salvinorin A or Divinorin A), meaning any extract from any part |
11 | of the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall |
12 | not mean the unaltered plant. |
13 | (26) Datura stamonium (jimsom weed or datura), meaning any extract from any part of |
14 | the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall not |
15 | mean the unaltered plant. |
16 | (e) Depressants. Unless specifically excepted or unless listed in another schedule, any |
17 | material, compound, mixture, or preparation that contains any quantity of the following |
18 | substances having a depressant effect on the central nervous system, including its salts, isomers, |
19 | and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible |
20 | within the specific chemical designation: |
21 | (1) Mecloqualone. |
22 | (2) Methaqualone. |
23 | (3) 3-methyl fentanyl (n-(3methyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. |
24 | (4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional, and |
25 | geometric isomers, salts, and salts of isomers. |
26 | (5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and |
27 | salts of isomers. |
28 | (6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts, |
29 | and salts of isomers. |
30 | (7) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl-alpha- |
31 | methylfentanyl), its optical isomers, salts, and salts of isomers. |
32 | (8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami de (alpha- |
33 | methylthiofentanyl), its optical isomers, salts, and salts of isomers. |
34 | (9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers, |
| LC000191 - Page 5 of 17 |
1 | salts, and salts of isomers. |
2 | (10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta- |
3 | hydroxyfentanyl), its optical isomers, salts, and salts of isomers. |
4 | (11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta- |
5 | hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers. |
6 | (12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro- panamide (3- |
7 | methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers. |
8 | (13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its |
9 | optical isomers, salts, and salts of isomers. |
10 | (14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical |
11 | isomers, salts, and salts of isomers. |
12 | (15) N-[1-(2-phenylethyl)-4-piperidyl] N-(4-fluorophenyl)-propanamid e (para- |
13 | fluorofentanyl), its optical isomers, salts, and salts of isomers. |
14 | (16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or |
15 | geometric isomers, salts, and salts of isomers. |
16 | (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
17 | material, compound, mixture, or preparation that contains any quantity of the following |
18 | substances having a stimulant effect on the central nervous system, including its salts, isomers, |
19 | and salts of isomers: |
20 | (1) Fenethylline |
21 | (2) N-ethylamphetamine |
22 | (3) 4-methyl-N-methylcathinone (Other name: mephedrone) |
23 | (4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone) |
24 | (5) 3,4-methylenedioxypyrovalerone (Other name: MDPV) |
25 | (g) Any material, compound, mixture, or preparation that contains any quantity of the |
26 | following substances: |
27 | (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl] phenol (CP-47,497) |
28 | (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl] phenol |
29 | (cannabicyclohexanol and CP-47,497 c8 homologue) |
30 | (3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073) |
31 | (4) 1-[2-(4-Morpholinyl)ethyl] 3-(1-naphthoyl)indole (JWH-200) |
32 | (5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678) |
33 | (h) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical |
34 | compound which is not approved by the United States Food and Drug Administration or, if |
| LC000191 - Page 6 of 17 |
1 | approved, which is not dispensed or possessed in accordance with state and federal law, that |
2 | contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1- |
3 | Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1- |
4 | Pentyl-3-(1-naphthoyl) indole; dexanabinol (HU-211); or any compound in the following |
5 | structural classes: |
6 | (1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with |
7 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
8 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
9 | group, whether or not further substituted in the indole ring to any extent and whether or not |
10 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
11 | limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM- |
12 | 2201; |
13 | (2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with |
14 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
15 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
16 | group whether or not further substituted in the indole ring to any extent and whether or not |
17 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
18 | limited to, JWH-167, JWH-250, JWH-251, and RCS-8; |
19 | (3) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with |
20 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
21 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
22 | group whether or not further substituted in the indole ring to any extent and whether or not |
23 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
24 | limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
25 | (4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol |
26 | structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, |
27 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
28 | group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural |
29 | class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); |
30 | (5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) |
31 | methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, |
32 | alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- |
33 | morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and |
34 | whether or not substituted in the naphthyl ring to any extent. Examples of this structural class |
| LC000191 - Page 7 of 17 |
1 | include, but are not limited to, JWH-175, JWH-184, and JWH-185; |
2 | (6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure |
3 | with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, |
4 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
5 | group whether or not further substituted in the pyrrole ring to any extent and whether or not |
6 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
7 | limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
8 | (7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene |
9 | structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, |
10 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
11 | group whether or not further substituted in the indene ring to any extent and whether or not |
12 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
13 | limited to, JWH-176; or |
14 | (8) Any other synthetic cannabinoid or piperazine which is not approved by the United |
15 | States Food and Drug Administration or, if approved, which is not dispensed or possessed in |
16 | accordance with state and federal law; |
17 | (i) Synthetic cathinones. Unless specifically excepted, any chemical compound which is |
18 | not approved by the United States Food and Drug Administration or, if approved, which is not |
19 | dispensed or possessed in accordance with state and federal law, not including bupropion, |
20 | structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either |
21 | phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in |
22 | one or more of the following ways: |
23 | (1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, |
24 | haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system |
25 | by one or more other univalent substituents. Examples of this class include, but are not limited to, |
26 | 3,4-Methylenedioxycathinone (bk-MDA); |
27 | (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this |
28 | class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); |
29 | (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or |
30 | methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. |
31 | Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and a- |
32 | Pyrrolidinopropiophenone (a-PPP); or |
33 | (4) Any other synthetic cathinone which is not approved by the United States Food and |
34 | Drug Administration or, if approved, is not dispensed or possessed in accordance with state or |
| LC000191 - Page 8 of 17 |
1 | federal law; |
2 | Schedule II |
3 | (a) Schedule II shall consist of the drugs and other substances, by whatever official name, |
4 | common or usual name, chemical name, or brand name designated, listed in this section. |
5 | (b) Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or |
6 | unless listed in another schedule, any of the following substances whether produced directly or |
7 | indirectly by extraction from substances of vegetable origin, or independently by means of |
8 | chemical synthesis, or by a combination of extraction and chemical synthesis: |
9 | (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or |
10 | opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the |
11 | following: |
12 | (i) Raw opium |
13 | (ii) Opium extracts |
14 | (iii) Opium fluid extracts |
15 | (iv) Powdered opium |
16 | (v) Granulated opium |
17 | (vi) Tincture of opium |
18 | (vii) Etorphine hydrochloride |
19 | (viii) Codeine |
20 | (ix) Ethylmorphine |
21 | (x) Hydrocodone |
22 | (xi) Hydromorphone |
23 | (xii) Metopon |
24 | (xiii) Morphine |
25 | (xiv) Oxycodone |
26 | (xv) Oxymorphone |
27 | (xvi) Thebaine |
28 | (2) Any salt, compound, derivative, or preparation that is chemically equivalent or |
29 | identical with any of the substances referred to in subdivision (1) of this subsection, except that |
30 | these substances shall not include the isoquinoline alkaloids of opium. |
31 | (3) Opium poppy and poppy straw. |
32 | (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and |
33 | any salt, compound, derivative, or preparation that is chemically equivalent or identical with any |
34 | of these substances, except that the substances shall not include decocainized coca leaves or |
| LC000191 - Page 9 of 17 |
1 | extraction of coca leaves, which extractions do not contain cocaine or ecgonine. |
2 | (5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or |
3 | powder form that contains the phenanthrine alkaloids of the opium poppy). |
4 | (c) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
5 | following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters, and |
6 | ethers whenever the existence of the isomers, esters, ethers, and salts is possible within the |
7 | specific chemical designation: |
8 | (1) Alphaprodine |
9 | (2) Anileridine |
10 | (3) Bezitramide |
11 | (4) Dihydrocodeine |
12 | (5) Diphenoxylate |
13 | (6) Fentanyl |
14 | (7) Isomethadone |
15 | (8) Levomethorphan |
16 | (9) Levorphanol |
17 | (10) Metazocine |
18 | (11) Methadone |
19 | (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane |
20 | (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic |
21 | acid |
22 | (14) Pethidine |
23 | (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine |
24 | (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate |
25 | (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid |
26 | (18) Phenaxocine |
27 | (19) Piminodine |
28 | (20) Racemethorphan |
29 | (21) Racemorphan |
30 | (22) Bulk Dextropropoxyphene (non-dosage forms) |
31 | (23) Suffentanil |
32 | (24) Alfentanil |
33 | (25) Levoalphacetylmethadol |
34 | (d) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
| LC000191 - Page 10 of 17 |
1 | material, compound, mixture, or preparation that contains any quantity of the following |
2 | substances having a stimulant effect on the central nervous system: |
3 | (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers. |
4 | (2) Methamphetamine, its salts, and salts of its isomers. |
5 | (3) Phenmetrazine and its salts. |
6 | (4) Methylphenidate. |
7 | (e) Depressants. Unless specifically excepted or unless listed in another schedule, any |
8 | material, compound, mixture, or preparation that contains any quantity of the following |
9 | substances having a depressant effect on the central nervous system, including its salts, isomers, |
10 | and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible |
11 | within the specific chemical designation: |
12 | (1) Amobarbital |
13 | (2) Glutethimide |
14 | (3) Methyprylon |
15 | (4) Pentobarbital |
16 | (5) Phencyclidine |
17 | (6) Secobarbital |
18 | (7) Phencyclidine immediate precursors: |
19 | (i) 1-phencyclohexylamine |
20 | (ii) 1-piperidinocyclohexane-carbonitrile (PCC) |
21 | (8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some |
22 | other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone. |
23 | Schedule III |
24 | (a) Unless specifically excepted or unless listed in another schedule, any material, |
25 | compound, mixture, or preparation that contains any quantity of the following substances having |
26 | a depressant effect on the central nervous system: |
27 | (1) Any substance that contains any quantity of a derivative of barbituric acid or any salt |
28 | of a derivative of barbituric acid. |
29 | (2) Chlorhexadol |
30 | (3) Lysergic acid |
31 | (4) Lysergic acid amide |
32 | (5) Sulfondiethylmethane |
33 | (6) Sulfonethylmethane |
34 | (7) Sylfonmethane |
| LC000191 - Page 11 of 17 |
1 | (8) Any compound, mixture, or preparation containing amobarbital, secobarbital, |
2 | pentobarbital, or any salt of them and one or more other active medicinal ingredients that are not |
3 | listed in any schedule. |
4 | (9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or |
5 | any salt of any of these drugs and approved by the Food and Drug Administration for marketing |
6 | only as a suppository. |
7 | (10) Ketamine, its salts, isomers, and salts of isomers. (Some other names for ketamine: |
8 | (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone). |
9 | (b) Unless specifically excepted or unless listed in another schedule, any material, |
10 | compound, mixture, or preparation containing limited quantities of any of the following narcotic |
11 | drugs, or any salts of them: |
12 | (1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
13 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal |
14 | or greater quantity of an isoquinoline alkaloid of opium. |
15 | (2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
16 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
17 | more active, nonnarcotic ingredients in recognized therapeutic amounts. |
18 | (3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
19 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
20 | a fourfold or greater quantity of an isoquinoline alkaloid of opium. |
21 | (4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
22 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
23 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
24 | (5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one |
25 | hundred milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with |
26 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
27 | (6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one |
28 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
29 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
30 | (7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred |
31 | milliliters (100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five |
32 | milligrams (25 mgs.) per dosage unit, with one or more active nonnarcotic ingredients in |
33 | recognized therapeutic amounts. |
34 | (8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters (100 |
| LC000191 - Page 12 of 17 |
1 | mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in |
2 | recognized therapeutic amounts. |
3 | (c) Stimulants. Unless specifically excepted or listed in another schedule, any material, |
4 | compound, mixture, or preparation that contains any quantity of the following substances having |
5 | a stimulant effect on the central nervous system, including its salts, isomers, and salts of the |
6 | isomers whenever the existence of the salts of isomers is possible within the specific chemical |
7 | designation: |
8 | (1) Benzphetamine |
9 | (2) Chlorphentermine |
10 | (3) Clortermine |
11 | (4) Mazindol |
12 | (5) Phendimetrazine |
13 | (d) Steroids and hormones. Anabolic steroids (AS) or human growth hormone (HGH), |
14 | excluding those compounds, mixtures, or preparations containing an anabolic steroid that because |
15 | of its concentration, preparation, mixture, or delivery system, has no significant potential for |
16 | abuse, as published in 21 CFR 1308.34, including, but not limited to, the following: |
17 | (1) Chlorionic gonadotropin |
18 | (2) Clostebol |
19 | (3) Dehydrochlormethyltestosterone |
20 | (4) Ethylestrenol |
21 | (5) Fluoxymesterone |
22 | (6) Mesterolone |
23 | (7) Metenolone |
24 | (8) Methandienone |
25 | (9) Methandrostenolone |
26 | (10) Methyltestosterone |
27 | (11) Nandrolone decanoate |
28 | (12) Nandrolone phenpropionate |
29 | (13) Norethandrolone |
30 | (14) Oxandrolone |
31 | (15) Oxymesterone |
32 | (16) Oxymetholone |
33 | (17) Stanozolol |
34 | (18) Testosterone propionate |
| LC000191 - Page 13 of 17 |
1 | (19) Testosterone-like related compounds |
2 | (20) Human Growth Hormone (HGH) |
3 | (e) Hallucinogenic substances. |
4 | (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in U.S. |
5 | Food and Drug Administration-approved drug product. (Some other names for dronabinol: (6aR- |
6 | trans)-6a, 7, 8, 10a- tetrahydro-6, 6, 9- trimethyl-3-pentyl-6H- dibenzo[b,d] yra n-1-ol,or(-)-delta- |
7 | 9(trans)-tetrahydrocannabinol.) |
8 | Schedule IV |
9 | (1) Barbital. |
10 | (2) Chloral betaine |
11 | (3) Chloral hydrate |
12 | (4) Ethchrovynol |
13 | (5) Ethinamate |
14 | (6) Methohexital |
15 | (7) Meprobamate |
16 | (8) Methylphenobarbital |
17 | (9) Paraldehyde |
18 | (10) Petrichloral |
19 | (11) Phenobarbital |
20 | (12) Fenfluramine |
21 | (13) Diethylpropion |
22 | (14) Phentermine |
23 | (15) Pemoline (including organometallic complexes and chelates thereof). |
24 | (16) Chlordiazepoxide |
25 | (17) Clonazepam |
26 | (18) Clorazepate |
27 | (19) Diazepam |
28 | (20) Flurazepam |
29 | (21) Mebutamate |
30 | (22) Oxazepam |
31 | (23) Unless specifically excepted or unless listed in another schedule, any material, |
32 | compound, mixture, or preparation that contains any quantity of the following substances, |
33 | including its salts: |
34 | Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3- methyl-2- |
| LC000191 - Page 14 of 17 |
1 | propronoxybutane). |
2 | (24) Prazepam |
3 | (25) Lorazepam |
4 | (26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25) |
5 | micrograms of atropine sulfate per dosage unit. |
6 | (27) Pentazocine |
7 | (28) Pipradrol |
8 | (29) SPA (-)-1-dimethylamino-1, 2-diphenylethane |
9 | (30) Temazepam |
10 | (31) Halazepam |
11 | (32) Alprazolam |
12 | (33) Bromazepam |
13 | (34) Camazepam |
14 | (35) Clobazam |
15 | (36) Clotiazepam |
16 | (37) Cloxazolam |
17 | (38) Delorazepam |
18 | (39) Estazolam |
19 | (40) Ethyl Ioflazepate |
20 | (41) Fludizaepam |
21 | (42) Flunitrazepam |
22 | (43) Haloxazolam |
23 | (44) Ketazolam |
24 | (45) Loprazolam |
25 | (46) Lormetazepam |
26 | (47) Medazepam |
27 | (48) Nimetazepam |
28 | (49) Nitrazepam |
29 | (50) Nordiazepam |
30 | (51) Oxazolam |
31 | (52) Pinazepam |
32 | (53) Tetrazepam |
33 | (54) Mazindol |
34 | (55) Triazolam |
| LC000191 - Page 15 of 17 |
1 | (56) Midazolam |
2 | (57) Quazepam |
3 | (58) Butorphanol |
4 | (59) Sibutramine |
5 | Schedule V |
6 | (a) Any compound, mixture, or preparation containing any of the following limited |
7 | quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal |
8 | ingredients in sufficient proportion to confer upon the compound, mixture, or preparation |
9 | valuable medicinal qualities other than those possessed by the narcotic drug alone: |
10 | (1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100 |
11 | mls.) or per one hundred grams (100 gms.). |
12 | (2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 |
13 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
14 | (3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 |
15 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
16 | (4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less |
17 | than twenty-five (25) micrograms of atropine sulfate per dosage unit. |
18 | (5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred |
19 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
20 | (b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than twenty- |
21 | five (25) micrograms of atropine sulfate per dosage unit. |
22 | (c) Buprenorphine |
23 | (d) Unless specifically exempted or excluded or unless listed in another schedule, any |
24 | material, compound, mixture, or preparation that contains any quantity of the following |
25 | substances having a stimulant effect on the central nervous system, including its salts, isomers, |
26 | and salts of isomers: |
27 | (1) Propylhexedrine (except as benzedrex inhaler) |
28 | (2) Pyrovalerone. |
29 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC000191 | |
======== | |
| LC000191 - Page 16 of 17 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO FOOD AND DRUGS-UNIFORM CONTROLLED SUBSTANCES ACT | |
*** | |
1 | This act would add the synthetic opioid U-47700 3,4-dichloro-N-[2-(dimethylamino) |
2 | cyclohexyl]-N-methylbenzamidem) to the list of Schedule I controlled substances as enumerated |
3 | in ยง21-28-2.08 of the general laws. |
4 | This act would take effect upon passage. |
======== | |
LC000191 | |
======== | |
| LC000191 - Page 17 of 17 |